(19)
(11) EP 3 141 543 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
08.06.2022 Bulletin 2022/23

(45) Mention of the grant of the patent:
02.03.2022 Bulletin 2022/09

(21) Application number: 15789923.8

(22) Date of filing: 25.03.2015
(51) International Patent Classification (IPC): 
C07D 295/205(2006.01)
C07D 295/096(2006.01)
C07D 295/185(2006.01)
(52) Cooperative Patent Classification (CPC):
C07D 295/185; C07D 295/205; C07D 295/096
(86) International application number:
PCT/CN2015/075018
(87) International publication number:
WO 2015/169130 (12.11.2015 Gazette 2015/45)

(54)

VORTIOXETINE INTERMEDIATE AND SYNTHESIS PROCESS THEREOF

VORTIOXETIN-ZWISCHENPRODUKT UND SYNTHESEVERFAHREN DAFÜR

INTERMÉDIAIRE DE VORTIOXÉTINE ET SON PROCÉDÉ DE SYNTHÈSE


(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 09.05.2014 CN 201410193538

(43) Date of publication of application:
15.03.2017 Bulletin 2017/11

(73) Proprietors:
  • Shanghai Syncores Technologies Inc. Ltd.
    Shanghai 201203 (CN)
  • Zhejiang Huahai Pharmaceutical Co., Ltd
    Taizhou, Zhejiang 317024 (CN)

(72) Inventors:
  • TANG, Caide
    Shanghai 201203 (CN)
  • WANG, Gang
    Shanghai 201203 (CN)
  • WANG, Boyu
    Shanghai 201203 (CN)
  • HUANG, Luning
    Shanghai 201203 (CN)
  • GU, Eric
    Shanghai 201203 (CN)

(74) Representative: Pfenning, Meinig & Partner mbB 
Patent- und Rechtsanwälte Theresienhöhe 11a
80339 München
80339 München (DE)


(56) References cited: : 
EP-A1- 0 548 798
WO-A1-2011/072174
CN-A- 1 541 214
EP-A2- 0 957 099
WO-A1-2013/102573
   
  • BANG-ANDERSEN, BENNY ET AL.: 'Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl) phenyl] piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder' JOURNAL OF MEDICINAL CHEMISTRY vol. 54, no. 9, 12 April 2011, ISSN 0022-2623 pages 3206 - 3221, XP055058222
  • ANDERSEN, VALDEMAR L. ET AL.: '11C-labeling and preliminary evaluation of vortioxetine as a PET radioligand' BIOORGANIC & MEDICINAL CHEMISTRY LETTERS vol. 24, no. 11, 19 April 2014, ISSN 0960-894X pages 2408 - 2411, XP028660040
  • BANG-ANDERSEN, BENNY ET AL.: 'Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]pip erazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive Disorder' JOURNAL OF MEDICINAL CHEMISTRY vol. 54, no. 9, 12 April 2011, ISSN 0022-2623 pages 3206 - 3221, XP055058222
  • KRAFFT, EVA A. ET AL.: 'An improved synthesis of Lu AA20465' TETRAHEDRON LETTERS vol. 47, no. 30, 09 June 2006, ISSN 0040-4039 pages 5355 - 5357, XP025004533
  • SEGAWA, J. ET AL.: "Studies on Pyridonecarboxylic Acids. 1. Synthesis and Antibacterial Evaluation of 7-Substituted-6-halo-4-oxo-4H-[1,3]thiazet o[3,2-a]quinoline-3-carboxylic Acids", JOURNAL OF MEDICINAL CHEMISTRY, vol. 35, 1992, pages 4727-4738,
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).